Opinion|Videos|November 8, 2024
From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies
Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.
Advertisement
- Dr Rotow: The ALINA study included exploratory biomarker analyses in patients with resected ALK-positive NSCLC treated with adjuvant alectinib vs chemotherapy. (
Solomon BJ, et al. 2024. ESMO. 1206MO ) - What are your thoughts on these findings, and how might they impact your approach to early-stage ALK-positive NSCLC management?
- What strategies are you currently using for sequencing ALK inhibitors?
- How do resistance mechanisms influence your sequence decisions?
- What data support using lorlatinib in the first-line setting vs reserving it for later lines?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5


































